제넥신 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 용예령, was filed 22 Oct 2024.
제넥신: what insiders have been doing
제넥신 is a Health Care company. Its directors and officers file their transactions with DART (FSS). The last twelve months, up to 5 November 2026, brought 1 filing signed by 1 insider.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Across the 2,656 companies tracked on its exchange, the median is 7 filings; at 1 filing, this issuer sits below that mark. The full history, which starts in 2021, counts 27 purchases against no sales.
Insider buying of 제넥신 has been absent for the past year.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -42.9%Entry ₩15,050 · Close at T+365 ₩8,600
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- ●Executives0DART
- ●Executives0DART
- 563,723 sharesShareKRXDART:20241022000185Canonical exit: 20 Jan 2025 (T+90)
- 156,632 sharesShareKRXDART:20241022000186Canonical exit: 20 Jan 2025 (T+90)
- 1,691,165 sharesShareKRXDART:20241022000184Canonical exit: 20 Jan 2025 (T+90)
- 732,910 sharesKRXDART:20241010000633Canonical exit: 29 Dec 2024 (T+90)
- ●Executives0DART
- ShareKRXDART:20231030000037Canonical exit: 28 Jan 2024 (T+90)
- ●Executives0DART
- 1,682 shares@ ₩15,760.00100.0% of flowShareKRXDART:20230214000059Canonical exit: 15 May 2023 (T+90)
- 428 sharesShareKRXDART:20230116000037
- 599 sharesShareKRXDART:20230116000033
- 857 sharesShareKRXDART:20230116000025
- 1,239 sharesShareKRXDART:20230116000019
- 605,272 sharesShareKRXDART:20230116000016
- 1,395,815 sharesShareKRXDART:20230113000045
- ShareKRXDART:20221129000981Canonical exit: 27 Feb 2023 (T+90)
- ShareKRXDART:20221129000302Canonical exit: 27 Feb 2023 (T+90)
- ShareKRXDART:20221129000261Canonical exit: 27 Feb 2023 (T+90)
- ShareKRXDART:20221129000230Canonical exit: 27 Feb 2023 (T+90)
- ShareKRXDART:20221129000204Canonical exit: 27 Feb 2023 (T+90)
- ShareKRXDART:20221129000176Canonical exit: 27 Feb 2023 (T+90)
- ShareKRXDART:20221110000026Canonical exit: 8 Feb 2023 (T+90)
- ShareKRXDART:20221109000003Canonical exit: 7 Feb 2023 (T+90)
25 of 40 declarations
About 제넥신
Genexine is a biotechnology company focused on developing innovative therapeutics for autoimmune diseases and cancers. It is listed on the XKRX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
